A comprehensive review of six trials involving nearly 800,000 men found that prostate-specific antigen blood testing reduces prostate cancer deaths by two per 1,000 men screened, but many face unnecessary treatment and complications like incontinence and impotence. Researchers emphasized the small absolute benefit and called for shared decision-making between doctors and patients rather than universal screening programs.
Topicle Beta
1 comment
A comprehensive review of six trials involving nearly 800,000 men found that prostate-specific antigen blood testing reduces prostate cancer deaths by two per 1,000 men screened, but many face unnecessary treatment and complications like incontinence and impotence. Researchers emphasized the small absolute benefit and called for shared decision-making between doctors and patients rather than universal screening programs.